key: cord-0715048-ws0s2qk1 authors: Patanavanich, R.; Glantz, S. A. title: Smoking is Associated with COVID-19 Progression: A Meta-Analysis date: 2020-04-16 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.04.13.20063669 sha: 6fffd29da38651e79d21fe3d018164d10d336653 doc_id: 715048 cord_uid: ws0s2qk1 Objective: To determine the association between smoking and progression of COVID-19. Design: A meta-analysis of 12 published papers. Data Source: PubMed database was searched on April 6, 2020. Eligibility criteria and data analysis: We included studies reporting smoking behavior of COVID-19 patients and progression of disease. Search terms included smoking, smoker*, characteristics, risk factors, outcomes, and COVID-19, COVID, coronavirus, sar cov-2, sar cov 2. There were no language limitations. One author extracted information for each study, screened the abstract or the full text, with questions resolved through discussion among both authors. A random effects meta-analysis was applied. Main Outcome Measures: The study outcome was progression of COVID-19 among people who already had the disease. Results: We identified 12 papers with a total of 9,025 COVID-19 patients, 878 (9.7%) with severe disease and 495 with a history of smoking (5.5%). The meta-analysis showed a significant association between smoking and progression of COVID-19 (OR 2.25, 95% CI 1.49-3.39, p=0.001). Limitations in the 12 papers suggest that the actual risk of smoking may be higher. Conclusions: Smoking is a risk factor for progression of COVID-19, with smokers having higher odds of COVID-19 progression than never smokers. Physicians and public health professionals should collect data on smoking as part of clinical management and add smoking cessation to the list of practices to blunt the COVID-19 pandemic. COVID-19, the coronavirus-transmitted infectious disease, has caused a worldwide pandemic. Smoking 1 2 and e-cigarette use 3 increase risk and severity of pulmonary infections because of damage to upper airways and a decrease in pulmonary immune function. In particular, smokers have a higher risk of infection and mortality from Cov-MERS. 4 Two reviews 5 6 of the first 5 papers presenting data on smoking and COVID-19 reached different conclusions. Another review described 6 published case series presenting data on smoking among COVID-19 patients but did not draw a conclusion about the association of severity of COVID-19 with smoking. 7 We reviewed and summarized 12 papers presenting data on the association between smoking and severity of COVID-19. We conducted a systematic search using PubMed database on April 6, 2020, with the search term: ((smoking) OR (characteristics) OR (risk factors) OR (outcomes) OR (smoker*)) AND ((COVID-19) OR (COVID) OR (coronavirus) OR (sars cov-2) OR (sars cov 2)) for studies published between January 1, 2020 and April 6, 2020. There were no language restrictions. A total of 396 studies were retrieved through the search, of which 12, 10 from China, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 1 from Korea, 18 and 1 from the US, 19 included data on smoking behavior and COVID-19 disease progression (Table 1 ). Ten studies 8 10-18 were based on hospitalized patients and two 9 19 included both hospitalized patients and outpatients. The exposure group is those who had a history of smoking (current smokers or former smokers) and unexposed group was never smokers. Five studies 8 10 12 14 17 assessed whether the patient was a "current smoker," three studies 9 16 19 assessed whether the patient was a current or All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2020. . https://doi.org/10.1101/2020.04. 13.20063669 doi: medRxiv preprint former smoker (as separate categories), and four studies 11 13 15 18 assessed whether the patent had a "history of smoking" (current or former). Outcome is progression of COVID-19 to more severe or critical conditions or death (Table 1) . Two studies 14 16 categorized the outcome as severe (respiratory distress with respiratory rate ≥30/min, or oxygen saturation ≤93% at rest, or oxygenation index ≤300 mmHg, based on the diagnostic and treatment guideline for SARS-CoV-2 issued by Chinese National Health Committee 16 ) or mild, three 8 11 12 categorized the outcome as progression or improvement, two 10 19 categorized the outcome as ICU admission or non-ICU admission, one 9 categorized the outcome as the primary composite end point (ICU admission, the use of mechanical ventilation, or death) or not, two 15 17 categorized the outcome as death or survivor, one 13 categorized the outcome as the occurrence of severe cases (without defining severe) or death or mild, and one 18 categorized the outcome as clinical deterioration during the hospitalization and needed supplemental oxygen therapy. We computed unadjusted odds ratios (OR) and 95% confidence interval (CI) for each study using the number of smokers (current and former) and never smokers with and without disease progression. Random effects meta-analysis was performed using the Stata 14.0 metan command and using metabias command with Harbord and Peters to test for the presence of publication bias. Patients or the public were not involved in the design, or conduct, or reporting of our research. We will widely disseminate our findings working with the media and interested clinical and public health groups. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2020. . https://doi.org/10.1101/2020.04.13.20063669 doi: medRxiv preprint A total of 9,025 COVID-19 patients included in our meta-analysis, 878 of whom (9.7%) experienced disease progression and 495 with a history of smoking (5.5%). A total of 88 patients with a history of smoking (17.8%) experienced disease progression, compared with 9.3% of never smoking patients. The meta-analysis showed an association between smoking and COVID-19 progression (OR 2.25, 95% CI 1.49-3.39, p=0.001) ( Figure 1 ). There was not significant heterogeneity among the studies (I 2 =28.9%, p=0.162) or publication bias (Harbord's p=0.155, Peters' p=0.668). Our analysis confirms that smoking is a risk factor for progression of COVID-19, with smokers having 2.25-times the odds of severe COVID-19 outcomes than never smokers. This finding contrasts with an earlier meta-analysis, 6 which included only 5 studies and used a nonstandard method to compute the meta-analysis. The finding that smoking is associated with COVID-19 progression is not surprising because of the adverse effects of smoking on pulmonary immune function. 1 2 Our study has several limitations. The definition of "smoking" sometimes includes former smokers and sometimes does not. Only three studies 9 16 19 separated current and former smokers in different categories, which was not enough data to do a meta-analysis for current and former smokers separately. Because the lung recovers after someone stops smoking, including former smokers in the exposed group biases the effect estimate to the null. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 20 18.5% in the Korean patients vs. 21.1% 21 (37.0% for men and 5.2% for women) in 2017, and 3.6% in the US patients vs. 13.7% 22 (15.6% for men and 12.0% for women) in 2018. It is highly likely that many smokers were misclassified as nonsmokers, which also biases the risk estimate toward the null. We computed and assessed unadjusted odds ratios based on the numbers of patients reported in the studies. Only one 11 None of these studies assessed e-cigarette use. All these limitations suggest that this analysis underestimates the risk of smoking in terms of increasing COVID-19 severity. All 12 studies were of patients who had already developed COVID-19, so the risk estimate we report does not represent the effect of smoking on the risk of contracting COVID-19 in the general population. As population-level testing ramps up, it would be useful to collect data on smoking and e-cigarette use to determine what risks these behaviors impose in terms of infection. Smoking is associated with COVID-19 disease progression. Physicians and public health professionals should collect data on smoking and, given the pulmonary effects of e-cigarettes, 3 e-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2020. from the corresponding author) and declare that the work was supported as described in the funding statement above. The authors have no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work. RP developed the idea for the study, collected, analyzed the data, and wrote the first draft of the manuscript. SAG assisted with revising and refining the manuscript. Both authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All data used to prepare this paper are available from the cited sources. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Smoking and COVID-19 Progression All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2020. . https://doi.org/10.1101/2020.04. 13.20063669 doi: medRxiv preprint Cigarette smoking and infection The Influence of Cigarette Smoking on Viral Infections: Translating Bench Science to Impact COPD Pathogenesis and Acute Exacerbations of COPD Clinically What are the respiratory effects of e-cigarettes? MERS transmission and risk factors: a systematic review COVID-19 and smoking: A systematic review of the evidence Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19) COVID-19 and smoking Eleven Faces of Coronavirus Disease No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Clinical Characteristics of Coronavirus Disease Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19 Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States Tobacco and the lung cancer epidemic in China